# Bioequivalence of a New Sublingual and a Reference Alprazolam Immediate Release Tablet Formulation

> **NCT01027689** · PHASE1 · WITHDRAWN · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** alprazolam commercial immediate release oral tablet
- **DRUG:** alprazolam test sublingual tablet

## Key facts

- **NCT ID:** NCT01027689
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-04
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01027689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01027689, "Bioequivalence of a New Sublingual and a Reference Alprazolam Immediate Release Tablet Formulation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01027689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*